Opus GeneticsFRA:R3X1 -3.30%22 Market Cap is €295.45 Mil as of Jul. 07, 2026. GuruFocus rates FRA:R3X1 with a GF Score™ of 22/100 and a GF Value™ of €0.32 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,421 Biotechnology companies, Opus Genetics ranks better than 65.52% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Opus Genetics's share price for the quarter that ended in Mar. 2026 was €3.935. Opus Genetics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 71.40 Mil. Therefore, Opus Genetics's market cap for the quarter that ended in Mar. 2026 was €280.97 Mil.
Opus Genetics's quarterly market cap
increased
from Sep. 2025 (€89.33 Mil) to Dec. 2025 (€115.75 Mil) and
increased
from Dec. 2025 (€115.75 Mil) to Mar. 2026 (€280.97 Mil).
Opus Genetics's annual market cap
declined
from Dec. 2023 (€66.90 Mil) to Dec. 2024 (€34.35 Mil) but then
increased
from Dec. 2024 (€34.35 Mil) to Dec. 2025 (€115.75 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Opus Genetics's Enterprise Value for Today is €243.85 Mil.
Opus Genetics (FRA:R3X1) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Opus Genetics Market Cap Related Terms
Opus Genetics Market Cap Historical Data
* Premium members only.
The historical data trend for Opus Genetics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:R3X1 vs PALI, VSTM, GALT: Market Cap Comparison
For the Biotechnology subindustry, Opus Genetics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's Market Cap distribution charts can be found below:
* The bar in red indicates where Opus Genetics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Opus Genetics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (FRA:R3X1) has a Market Cap of €295.45 Mil as of Jul. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Opus Genetics and its competitors. According to the industry distribution chart, Opus Genetics ranks #490 out of 1421 companies in the Biotechnology industry, placing it in the top 34.5%.
Is Opus Genetics' Market Cap too high?
Opus Genetics' current Market Cap is €295.45 Mil. Based on the distribution chart, Opus Genetics ranks #490 out of 1421 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Opus Genetics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Market Cap compare to PALI and VSTM?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #490 out of 1421 companies for Market Cap. This puts Opus Genetics in the upper half of its industry. The industry median Market Cap is 121.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.57, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Opus Genetics and its competitors. For the Biotechnology industry, the median Market Cap is 121.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Opus Genetics's current Market Cap is €295.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (FRA:R3X1) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.32, compared to a current price of €3.52 — trading 1000% above its estimated fair value. The current Market Cap is €295.45 Mil. Opus Genetics' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Opus Genetics (FRA:R3X1), the current Market Cap is €295.45 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (FRA:R3X1) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of €3.52 is trading 1000% above its estimated GF Value™ of €0.32.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for FRA:R3X1:
Market Cap: €295.45 Mil
GF Value™: €0.32 vs. price of €3.52 (1000% above fair value)
No single metric tells the full story. See the FRA:R3X1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
22GF Score
Get the complete analysis for FRA:R3X1
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:R3X1 has been successfully added to your 
